

Jhanelle E Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7805503/publications.pdf>

Version: 2024-02-01

20
papers

10,639
citations

687363

13
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

11539
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. <i>Clinical Lung Cancer</i> , 2022, 23, e69-e82.	2.6	31
2	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	27.6	99
3	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. <i>Lung Cancer</i> , 2021, 153, 90-98.	2.0	6
4	Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. , 2021, 9, e002118.		75
5	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	2.0	11
6	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	1.7	3
7	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, e1812-e1821.	3.7	15
8	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
9	A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. <i>Lung Cancer</i> , 2021, 159, 1-9.	2.0	28
10	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	27.0	1,725
11	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6623-6632.	7.0	96
12	Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2058-2063.	7.0	52
13	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
14	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	27.0	3,530
15	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S433-S450.	1.4	15
16	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1853-1862.	4.2	21
17	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 619-629.	3.8	4
18	HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. <i>Epigenomics</i> , 2016, 8, 1015-1017.	2.1	22

#	ARTICLE	IF	CITATIONS
19	BRAF V600E mutations: a series of case reports in patients with non-“small cell lung cancer. <i>Cancer Genetics</i> , 2015, 208, 351-354.	0.4	9
20	Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 828-833.	0.8	11